Taken together, our data demonstrated, in colon cancer cells, the effectiveness of combined treatments with PPARγ agonists and a JNK inhibitor in reducing cell adhesion and migration, and are in agreement to the data indicating a positive interaction between PPARγ ligands and anti-inflammatory agents in humans [43]. Here, PPARG is linked to colonic neoplasm.